Showing results (421-430 of 511) with videos related to
Sort By:
Pageof 52
Journal of Thoracic Imaging|December 9, 2017
Computed Tomography Features associated With the Eighth Edition TNM Stage Classification for Thymic Epithelial TumorsSukhmani K Padda, Donato Terrone, Lu Tian, et al.Diabetes, Obesity & Metabolism|June 12, 2019
Peripherally delivered hepatopreferential insulin analog insulin-406 mimics the hypoglycaemia-sparing effect of portal vein human insulin infusion in dogsJustin M Gregory, Guillaume Kraft, Melanie F Scott, et al.JCO Precision Oncology|June 21, 2021
Randomized Phase II Study of 3 Months or 2 Years of Adjuvant Afatinib in Patients With Surgically Resected Stage I-III EGFR-Mutant Non-Small-Cell Lung CancerJoel W Neal, Daniel B Costa, Alona Muzikansky, et al.Practical Radiation Oncology|July 20, 2022
Isolated Nodal Recurrence After Definitive Stereotactic Ablative Radiation Therapy for Non-Small Cell Lung CancerMax Devine, David J Merriott, Hyunsoo J No, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 11, 2012
A phase I study of erlotinib and hydroxychloroquine in advanced non-small-cell lung cancerSarah B Goldberg, Jeffrey G Supko, Joel W Neal, et al.British Journal of Cancer|December 3, 2013
A phase II multicentre study of ziv-aflibercept in combination with cisplatin and pemetrexed in patients with previously untreated advanced/metastatic non-squamous non-small cell lung cancerH Chen, M R Modiano, J W Neal, et al.Journal of Neuro-Oncology|January 8, 2021
Improved survival and disease control following pembrolizumab-induced immune-related adverse events in high PD-L1 expressing non-small cell lung cancer with brain metastasesMichael Zhang, Adrian J Rodrigues, Erqi L Pollom, et al.Translational Lung Cancer Research|July 14, 2022
Clinicopathological characteristics and prognostic significance of HDAC11 protein expression in non-small cell lung cancer: a retrospective studyDi Lu, Zhiqiang Ma, Di Huang, et al.Proceedings of the National Academy of Sciences of the United States of America|January 22, 2015
Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancerRebecca S Heist, Dan G Duda, Dushyant V Sahani, et al.Lung Cancer (Amsterdam, Netherlands)|September 16, 2025
Clinical factors and molecular co-alterations impact outcomes in patients receiving first-line osimertinib for EGFR-mutated non-small cell lung cancerFangdi Sun, Mandeep K Banwait, Surbhi Singhal, et al.Pageof 52